Zentis Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.50 M
as on 16-11-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.60 M
as on 16-11-2024
- Revenue -25.48%
(FY 2023)
- Profit -377.23%
(FY 2023)
- Ebitda -118.43%
(FY 2023)
- Net Worth -21.47%
(FY 2023)
- Total Assets -3.06%
(FY 2023)
About Zentis Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.60 M.
Sanchit Sidana, Neelam Nirankari, and Surinder Singh serve as directors at the Company.
- CIN/LLPIN
U24100HR2010PTC040302
- Company No.
040302
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Mar 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
- Apps
What products or services does Zentis Drugs Private Limited offer?
Zentis Drugs Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Vitamins & Supplements, Multivitamins.
Who are the key members and board of directors at Zentis Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanchit Sidana  | Director | 11-Nov-2016 | Current |
| Neelam Nirankari | Director | 04-Jan-2014 | Current |
| Surinder Singh | Director | 04-Jun-2011 | Current |
Financial Performance and Corporate Structure Insights of Zentis Drugs.
Zentis Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 25.48% decrease. The company also saw a substantial fall in profitability, with a 377.23% decrease in profit. The company's net worth observed a substantial decline by a decrease of 21.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zentis Drugs?
In 2023, Zentis Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Guelph Healthcare Private LimitedActive 3 years 2 monthsNeelam Nirankari and Surinder Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Icici Bank Limited Creation Date: 24 Jun 2014 | ₹2.60 M | Open |
How Many Employees Work at Zentis Drugs?
Unlock and access historical data on people associated with Zentis Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zentis Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zentis Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
